Subcellular injuries in Alzheimer's disease

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 4, 2014, Pages 593-605

  Tillement, Jean Paul ^a,b   Papadopoulos, Vassilios ^a,b,c  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ACADÉMIE NATIONALE DE MÉDECINE   (France)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Endoplasmic reticulum; Golgi; Lysosomes; Mitochondria; Neurons; Nucleus; Plasma membrane; amyloid

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; ADENINE NUCLEOTIDE TRANSLOCASE; ALCOHOL DEHYDROGENASE; AMPA RECEPTOR; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; CATHEPSIN; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CRYOPYRIN; CYCLIN DEPENDENT KINASE 5; CYCLOPHILIN D; CYCLOSPORIN A; CYTOCHROME P450; GLYCOGEN SYNTHASE KINASE 3; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MICROTUBULE ASSOCIATED PROTEIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; PEROXIREDOXIN 2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TAU PROTEIN; UNINDEXED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

ALZHEIMER DISEASE; AMYLOID PLAQUE; APOPTOSIS; ASTROCYTE; AUTOPSY; BIOACCUMULATION; CALCIUM HOMEOSTASIS; CELL DEATH; CELL MEMBRANE PERMEABILITY; ENDOPLASMIC RETICULUM; ENDOSOME; GOLGI COMPLEX; LYSOSOME; MICROGLIA; MITOCHONDRION; NERVE CELL DEGENERATION; NERVE INJURY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SYNAPTIC TRANSMISSION; UNFOLDED PROTEIN RESPONSE; ANIMAL; BRAIN; HUMAN; IMMUNOMODULATION; INTRACELLULAR SPACE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CELL DEATH; HUMANS; INTRACELLULAR SPACE; NEUROIMMUNOMODULATION;

EID: 84904458752     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660197     Document Type: Review

References (134)

1. Williams M. Progress in Alzheimer's disease drug discovery: an update. Curr Opin Investig Drugs 2009; 10(1): 23-34.
2. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293(5534): 1491-5.
3. Griffin WS. Excess beta CTF, not Abeta: the culprit in Alzheimerrelated endocytic dysfunction. Proc Natl Acad Sci USA 2010; 107(4): 1263-1264.
4. Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 2010; 20(Suppl 2): S265-79.
5. Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004; 10(10): 1055-63.
6. Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009; 106(10): 4012-4017.
7. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci 2000; 113(Pt 11): 1857-70.
8. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008; 283(44): 29615-9.
9. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci 2003; 23(13): 5531-5535.
10. Sevalle J, Amoyel A, Robert P, et al. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J Neurochem 2009; 109(1): 248-256.
11. Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci 1993; 16(10): 403-9.
12. Rosenberg RN. The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture. Neurology 2000; 54(11): 2045-2054.
13. Haass C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993; 75(6): 1039-42.
14. Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 2004; 23(1-2): 105-14.
15. Wolfe MS, De Los AJ, Miller DD, Xia W, Selkoe DJ. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. Biochemistry 1999; 38(35): 11223-30.
16. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Discov 2002; 1(11): 859-66.
17. Poduslo JF, Gilles EJ, Ramakrishnan M, et al. HH domain of Alzheimer's disease Abeta provides structural basis for neuronal binding in PC12 and mouse cortical/hippocampal neurons. PLoS One 2010; 5(1): e8813.
18. Vieira SI, Rebelo S, Domingues SC, et al. S655 phosphorylation enhances APP secretory traffic. Mol Cell Biochem 2009; 328(1-2): 145-54.
19. Burgos PV, Mardones GA, Rojas AL, et al. Sorting of the Alzheimer's disease amyloid precursor protein mediated by the AP- 4 complex. Dev Cell 2010; 18(3): 425-36.
20. Yao Z, Drieu K, Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res 2001; 889(1-2): 181-90.
21. Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002; 41(5): 345-52.
22. Look GC, Jerecic J, Cherbavaz DB, et al. Discovery of ADDL-- targeting small molecule drugs for Alzheimer's disease. Curr Alzheimer Res 2007; 4(5): 562-7.
23. Papadopoulos V, Lecanu L. Caprospinol: Discovery of a Steroid Drug Candidate to Treat Alzheimer's Disease Based on 22RHydroxycholesterol Structure and Properties. J Neuroendocrinol 2012; 24(1): 93-101.
24. Prasanthi JR, Dasari B, Marwarha G, et al. Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic Biol Med 2010; 49(7): 1212-20.
25. Zhang H, Ma Q, Zhang YW, Xu H. Proteolytic processing of Alzheimer's beta-amyloid precursor protein. J Neurochem 2012; 120(Suppl 1): 9-21.
26. Pardossi-Piquard R, Checler F. The physiology of the beta-amyloid precursor protein intracellular domain AICD. J Neurochem 2012; 120(Suppl 1): 109-24.
27. Parodi J, Sepulveda FJ, Roa J, et al. Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J Biol Chem 2010; 285(4): 2506-14.
28. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F betaamyloid precursor protein. Nature 1995; 373(6514): 523-7.
29. Sun KH, de Pablo Y, Vincent F, et al. Novel genetic tools reveal Cdk5's major role in Golgi fragmentation in Alzheimer's disease. Mol Biol Cell 2008; 19(7): 3052-69.
30. Dubelaar EJ, Mufson EJ, ter Meulen WG, et al. Increased metabolic activity in nucleus basalis of Meynert neurons in elderly individuals with mild cognitive impairment as indicated by the size of the Golgi apparatus. J Neuropathol Exp Neurol 2006; 65(3): 257-66.
31. Hu Z, Zeng L, Huang Z, Zhang J, Li T. The study of Golgi apparatus in Alzheimer's disease. Neurochem Res 2007; 32(8): 1265-77.
32. Mancini M, Machamer CE, Roy S, et al. Caspase-2 is localized at the Golgi complex and cleaves golgin-160 during apoptosis. J Cell Biol 2000; 149(3): 603-12.
33. Bernstein HG, Bruszis S, Schmidt D, Wiederanders B, Dorn A. Immunodetection of cathepsin D in neuritic plaques found in brains of patients with dementia of Alzheimer type. J Hirnforsch 1989; 30(5): 613-8.
34. Cataldo AM, Nixon RA. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci USA 1990; 87(10): 3861-3865.
35. Nixon RA, Cataldo AM. Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J Alzheimers Dis 2006; 9(3 Suppl): 277-289.
36. Ling D, Salvaterra PM. A central role for autophagy in Alzheimertype neurodegeneration. Autophagy 2009; 5(5): 738-40.
37. De Duve C, Wattiaux R. Functions of lysosomes. Annu Rev Physiol 1966; 28: 435-492.
38. Jiang Y, Mullaney KA, Peterhoff CM, et al. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci USA 2010; 107(4): 1630-5.
39. Yang DS, Stavrides P, Mohan PS, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 2011; 134(Pt 1): 258-77.
40. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298(5594): 789-91.
41. Eckert GP, Wood WG, Muller WE. Effects of aging and betaamyloid on the properties of brain synaptic and mitochondrial membranes. J Neural Transm 2001; 108(8-9): 1051-64.
42. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261(5123): 921-3.
43. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342(8873): 697-9.
44. Refolo LM, Malester B, LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 2000; 7(4): 321-31.
45. Sparks DL, Scheff SW, Hunsaker JC III, et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994; 126(1): 88-94.
46. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3- hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57(10): 1439-43.
47. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74(12): 956-64.
48. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95(11): 6460-6464.
49. Yao ZX, Papadopoulos V. Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J 2002; 16(12): 1677-9.
50. Renner M, Lacor PN, Velasco PT, et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010; 66(5): 739-54.
51. Rizzoli SO, Betz WJ. Synaptic vesicle pools. Nat Rev Neurosci 2005; 6(1): 57-69.
52. Arispe N, Diaz JC, Simakova O. Abeta ion channels. Prospects or treating Alzheimer's disease with Abeta channel blockers. Biochim Biophys Acta 2007; 1768(8): 1952-65.
53. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8(8): 1051-8.
54. Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27(4): 796-807.
55. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8(2): 101-12.
56. Tatsuta T, Langer T. Quality control of mitochondria: protection against neurodegeneration and ageing. EMBO J 2008; 27(2): 306-14.
57. Moreira PI, Siedlak SL, Wang X, et al. Increased autophagic degradation of mitochondria in Alzheimer disease. Autophagy 2007; 3(6): 614-5.
58. Yang TT, Hsu CT, Kuo YM. Cell-derived soluble oligomers of human amyloid-beta peptides disturb cellular homeostasis and induce apoptosis in primary hippocampal neurons. J Neural Transm 2009; 116(12): 1561-9.
59. Tillement L, Lecanu L, Papadopoulos V. Further evidence on mitochondrial targeting of beta-amyloid and specificity of betaamyloid- induced mitotoxicity in neurons. Neurodegener Dis 2011; 8(5): 331-44.
60. Tillement L, Lecanu L, Papadopoulos V. Alzheimer's disease: effects of beta-amyloid on mitochondria. Mitochondrion 2011; 11(1): 13-21.
61. Hansson Petersen CA, Alikhani N, Behbahani H, et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA 2008; 105(35): 13145-50.
62. Wang X, Su B, Lee HG, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 2009; 29(28): 9090-103.
63. Oettinghaus B, Licci M, Scorrano L, Frank S. Less than perfect divorces: dysregulated mitochondrial fission and neurodegeneration. Acta Neuropathol 2012; 123(2): 189-203.
64. Muirhead KE, Borger E, Aitken L, Conway SJ, Gunn-Moore FJ. The consequences of mitochondrial amyloid beta-peptide in Alzheimer's disease. Biochem J 2010; 426(3): 255-70.
65. Powell AJ, Read JA, Banfield MJ, et al. Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/amyloid-beta binding alcohol dehydrogenase (ABAD). J Mol Biol 2000; 303(2): 311-27.
66. Yao J, Taylor M, Davey F, et al. Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol Cell Neurosci 2007; 35(2): 377-82.
67. Du H, Guo L, Fang F, et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 2008; 14(10): 1097-105.
68. Kissinger CR, Rejto PA, Pelletier LA, et al. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics. J Mol Biol 2004; 342(3): 943-52.
69. Schlattner U, Tokarska-Schlattner M, Ramirez S, et al. Mitochondrial kinases and their molecular interaction with cardiolipin. Biochim Biophys Acta 2009; 1788(10): 2032-47.
70. Orsucci D, Mancuso M, Ienco EC, et al. Vascular Factors and Mitochondrial Dysfunction: a Central Role in the Pathogenesis of Alzheimer's Disease. Curr Neurovasc Res 2012; 10(1): 76-80.
71. Yao J, Irwin RW, Zhao L, et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106(34): 14670-14675.
72. Hoyer S. Abnormalities of glucose metabolism in Alzheimer's disease. Ann NY Acad Sci 1991; 640: 53-8.
73. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443(7113): 787-95.
74. Leuner K, Schutt T, Kurz C, et al. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal 2012; 16(12): 1421-33.
75. Leuner K, Muller WE, Reichert AS. From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Mol Neurobiol 2012; 46(1): 186-93.
76. Hauptmann S, Scherping I, Drose S, et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 2009; 30(10): 1574-86.
77. Rhein V, Song X, Wiesner A, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 2009; 106(47): 20057-62.
78. Ancolio K, Dumanchin C, Barelli H, et al. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. Proc Natl Acad Sci USA 1999; 96(7): 4119-24.
79. Lee JH, Barral S, Reitz C. The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer's disease. Curr Neurol Neurosci Rep 2008; 8(5): 384-91.
80. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41(10): 1088-93.
81. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41(10): 1094-9.
82. Reitz C, Mayeux R. Endophenotypes in normal brain morphology and Alzheimer's disease: a review. Neuroscience 2009; 164(1): 174-90.
83. van Es MA, van den Berg LH. Alzheimer's disease beyond APOE. Nat Genet 2009; 41(10): 1047-8.
84. Abdul HM, Furman JL, Sama MA, Mathis DM, Norris CM. NFATs and Alzheimer's Disease. Mol Cell Pharmacol 2010; 2(1): 7-14.
85. Buggia-Prevot V, Sevalle J, Rossner S, Checler F. NFkappaBdependent control of BACE1 promoter transactivation by Abeta42. J Biol Chem 2008; 283(15): 10037-47.
86. Tillement JP, Lecanu L, Papadopoulos V. Amyloidosis and neurodegenerative diseases: current treatments and new pharmacological options. Pharmacology 2010; 85(1): 1-17.
87. Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Soothing the inflamed brain: effect of non-steroidal antiinflammatory drugs on Alzheimer's disease pathology. CNS Neurol Disord Drug Targets 2011; 10(1): 57-67.
88. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009; 80(1): 13-7.
89. Butterfield DA, Barone E, Mancuso C. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res 2011; 64(3): 180-6.
90. Marciniak SJ, Yun CY, Oyadomari S, et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 2004; 18(24): 3066-77.
91. Stanga S, Lanni C, Govoni S, et al. Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link? Aging 2010; 2(9): 545-54.
92. Lanni C, Racchi M, Stanga S, et al. Unfolded p53 in blood as a predictive signature signature of the transition from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis 2010; 20(1): 97-104.
93. Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J. ER stress in Alzheimer's disease: a novel neuronal trigger for inflammation and Alzheimer's pathology. J Neuroinflammation 2009; 6: 41.
94. Katayama T, Imaizumi K, Manabe T, Hitomi J, Kudo T, Tohyama M. Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat 2004; 28(1-2): 67-78.
95. Ohta K, Mizuno A, Li S, et al. Endoplasmic reticulum stress enhances gamma-secretase activity. Biochem Biophys Res Commun 2011; 416(3-4): 362-6.
96. Yao ZX, Brown RC, Teper G, Greeson J, Papadopoulos V. 22RHydroxycholesterol protects neuronal cells from beta-amyloidinduced cytotoxicity by binding to beta-amyloid peptide. J Neurochem 2002; 83(5): 1110-9.
97. Menu P, Mayor A, Zhou R, et al. ER stress activates the NLRP3 inflammasome via an UPR-independent pathway. Cell Death Dis 2012; 3: e261.
98. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469(7329): 221-5.
99. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011; 243(1): 136-51.
100. Escames G, Lopez LC, Garcia JA, et al. Mitochondrial DNA and inflammatory diseases. Hum Genet 2012; 131(2): 161-73.
101. Tschopp J. Mitochondria: Sovereign of inflammation? Eur J Immunol 2011; 41(5): 1196-202.
102. Di FM, Chiasserini D, Tozzi A, Picconi B, Calabresi P. Mitochondria and the link between neuroinflammation and neurodegeneration. J Alzheimers Dis 2010; 20(Suppl 2): S369-79.
103. Lee M, Cho T, Jantaratnotai N, et al. Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J 2010; 24(7): 2533-45.
104. Abramov AY, Jacobson J, Wientjes F, et al. Expression and modulation of an NADPH oxidase in mammalian astrocytes. J Neurosci 2005; 25(40): 9176-84.
105. Mancardi D, Penna C, Merlino A, et al. Physiological and pharmacological features of the novel gasotransmitter: hydrogen sulfide. Biochim Biophys Acta 2009; 1787(7): 864-72.
106. Ting KK, Brew B, Guillemin G. The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. Neurotox Res 2007; 12(4): 247-62.
107. Dutheil F, Beaune P, Loriot MA. Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 2008; 90(3): 426-36.
108. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285(5431): 1276-9.
109. Pikuleva IA. Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos 2006; 34(4): 513-20.
110. Nagele RG, Wegiel J, Venkataraman V, et al. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 2004; 25(5): 663-74.
111. Mandrekar-Colucci S, Landreth GE. Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets 2010; 9(2): 156-67.
112. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003; 23(5): 1605-11.
113. Vilhardt F. Microglia: phagocyte and glia cell. Int J Biochem Cell Biol 2005; 37(1): 17-21.
114. Mrak RE. Neuropathology and the neuroinflammation idea. J Alzheimers Dis 2009; 18(3): 473-81.
115. Morales I, Farias G, Maccioni RB. Neuroimmunomodulation in the pathogenesis of Alzheimer's disease. Neuroimmunomodulation 2010; 17(3): 202-4.
116. Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D. Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J Neurochem 2009; 110(2): 469-485.
117. Jazwa A, Cuadrado A. Targeting heme oxygenase-1 for neuroprotection and neuroinflammation in neurodegenerative diseases. Curr Drug Targets 2010; 11(12): 1517-31.
118. Jaworski T, Kugler S, Van Leuven F. Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis 2010; 2010: pii.573138.
119. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8(9): 663-72.
120. Clinton LK, Blurton-Jones M, Myczek K, et al. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30(21): 7281-9.
121. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009; 118(1): 5-36.
122. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142(3): 387-97.
123. Iqbal K, Liu F, Gong CX, Alonso AC, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009; 118(1): 53-69.
124. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010; 7(8): 656-64.
125. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996; 274(5284): 99-102.
126. Nixon RA, Yang DS. Autophagy failure in Alzheimer's diseaselocating the primary defect. Neurobiol Dis 2011; 43(1): 38-45.
127. Shacka JJ, Roth KA, Zhang J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci 2008; 13: 718-36.
128. Frykman S, Hur JY, Franberg J, et al. Synaptic and endosomal localization of active gamma-secretase in rat brain. PLoS One 2010; 5(1): e8948.
129. Nixon RA. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiol Aging 2005; 26(3): 373-82.
130. Camins A, Verdaguer E, Folch J, Canudas AM, Pallas M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect 2006; 19(8): 453-60.
131. Petit-Paitel A. GSK-3beta: a central kinase for neurodegenerative diseases. Med Sci 2010; 26(5): 516-21.
132. Castro RE, Santos MM, Gloria PM, et al. Cell death targets and potential modulators in Alzheimer's disease. Curr Pharm Des 2010; 16(25): 2851-64.
133. Hellwig CT, Passante E, Rehm M. The molecular machinery regulating apoptosis signal transduction and its implication in human physiology and pathophysiologies. Curr Mol Med 2011; 11(1): 31-47.
134. Rohn TT. The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities. Apoptosis 2010; 15(11): 1403-9.